Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Sep 4;14(1):211.
doi: 10.1186/s13023-019-1175-5.

Haemophilia A: health and economic burden of a rare disease in Portugal

Andreia Café  1 , Manuela Carvalho  2 , Miguel Crato  3 , Miguel Faria  4 , Paula Kjollerstrom  5 , Cristina Oliveira  6 , Patrícia R Pinto  7   8 , Ramón Salvado  9 , Alexandra Aires Dos Santos  10 , Catarina Silva  4   11
Affiliations

Haemophilia A: health and economic burden of a rare disease in Portugal

Andreia Café et al. Orphanet J Rare Dis. .

Abstract

Background: Haemophilia A is a hereditary bleeding disorder, which has been considered rare and chronic. The burden of this disease in Portugal remains unknown. The aim of this study was to estimate the annualized cost and health burden of haemophilia A in Portugal.

Methods: Data were extracted from a Portuguese expert panel, from official data and national literature. Annual costs were calculated from the perspective of the society including direct and indirect costs. Unitary costs were extracted from 2017 national official sources and are expressed in euros. Health burden was expressed in disability adjusted life years (DALYs) based on incidence and quality of life questionnaires. Estimates are presented for the overall population and stratified by severity, age group (< 18 years vs. adults) and inhibitor status.

Results: The yearly average cost per patient is estimated to range from €39,654/patient without inhibitors and €302,189/patient with inhibitors, representing a 7.6 fold difference. Amongst patients without inhibitors, the annual average cost was €401 in mild, €5327 in moderate and €85,805 in severe disease. Average cost per child and adult is €72,287 and €51,737, respectively. Direct costs represent approximately 95% of all costs, of which almost the totality accounts for clotting factor replacement therapy and bypassing agents. The total annual cost of haemophilia A for the Portuguese society was estimated to be €42,66 million, one third of which was related to the treatment of patients with inhibitors. It is estimated that haemophilia A is responsible for 3878 DALYs in Portugal (497 DALYs in mild, 524 DALYs in moderate, 2031 DALYs in severe patients without inhibitors and 784 DALYs in patients with inhibitors) for the cohort of 2017 (750 patients) or 5.2 DALY/patient during lifetime.

Conclusions: Despite being rare, the economic and health burden of haemophilia A is remarkable. The main cost driver is clotting factor replacement therapy. Moreover, haemophilia A is more costly in children than in adults and rises exponentially with disease severity.

Keywords: Burden; Cost-of-illness; Disability-adjusted life year; Haemophilia A; Health economics; Portugal.

PubMed Disclaimer

Conflict of interest statement

The authors state that there is no financial or personal relationship with other individuals or entities which may influence their work inappropriately. AC is a full-time employee of Roche.

References

    1. Costa C, Frances AM, Letourneau S, Girodon-Boulandet E, Goossens M. Mosaicism in men in hemophilia: is it exceptional? Impact on genetic counselling. J Thromb Haemost. 2009;7(2):367–369. doi: 10.1111/j.1538-7836.2008.03246.x. - DOI - PMC - PubMed
    1. Mannucci PM, Tuddenham EGD. The Hemophilias — from Royal Genes to gene therapy. N Engl J Med. 2001;344(23):1773–1779. doi: 10.1056/NEJM200106073442307. - DOI - PubMed
    1. Berntorp E, Shapiro AD. Modern haemophilia care. Lancet. 2012;379(9824):1447–1456. doi: 10.1016/S0140-6736(11)61139-2. - DOI - PubMed
    1. Young G. New challenges in hemophilia: long-term outcomes and complications. Hematol Am Soc Hematol Educ Progr. 2012;2012(1):362–368. - PubMed
    1. Klamroth R, Pollmann H, Hermans C, Faradji A, Yarlas AS, Epstein JD, et al. The relative burden of haemophilia A and the impact of target joint development on health-related quality of life: results from the ADVATE Post-Authorization Safety Surveillance (PASS) study. Haemophilia. 2011;17(3):412–421. doi: 10.1111/j.1365-2516.2010.02435.x. - DOI - PubMed

Publication types